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Several selective serotonin reuptake inhibitors (SSRI), especially paroxetine, have been 
reported to produce a number of post-treatment emergent adverse events following 
abrupt withdrawal (Coupland et al 1996; Haddad 1997). More recently a SSRI-induced 
neonatal withdrawal syndrome has been described (Sanz et al 2005) in infants born of 
mothers treated with SSRI during pregnancy. In both of these situations, paroxetine 
has been associated with the greatest incidence (Warner et al 2006; Sanz et al 2005). 
Other SSRIs and the selective serotonin and noradrenaline reuptake inhibitor (SNRI) 
venlafaxine can, however also cause a withdrawal syndrome in patients (Trenque et al 
2002). In contrast, milnacipran, another SNRI, has been reported to present a lower risk 
of withdrawal-induced adverse events (Vandel et al 2004). Furthermore the spectrum 
of the symptoms was different from that produced by paroxetine.  
In our clinic, a discontinuation syndrome is sometimes seen when SSRIs or SNRIs 
are discontinued suddenly, or when doses are missed or forgotten. In a total cohort 
of 2675 depressed patients, we identiﬁ  ed 124 cases of antidepressant withdrawal 
syndrome. Sixty-three of the cases resulted from withdrawal from ﬂ  uvoxamine (from 
a total of 1306 treated patients), 55 were withdrawn from paroxetine (from a total of 
453 treated patients), while 6 were withdrawn from milnacipran (from a total of 916 
treated patients). With paroxetine and ﬂ  uvoxamine, respectively, the incidence of 
discontinuation syndrome was 18.4 times greater and 7.3 times greater than that found 
with milnacipran (Table1). These differences were highly signiﬁ  cant as determined by 
the χ2 test. These results are qualitatively similar to those obtained in a double-blind 
comparative study of milnacipran and paroxetine by Vandel et al (2004), who found 
an incidence of discontinuation syndrome of 13% with milnacipran and 32% with 
paroxetine following withdrawal after 6 weeks of treatment.
Paroxetine has systematically been found to have the highest incidence of discon-
tinuation syndrome (Warner et al 2006) while ﬂ  uvoxamine has an incidence 10-fold 
lower and ﬂ  uoxetine 100-fold lower (Westenberg and Sandner 2006). Paroxetine is 
the most potent inhibitor of the serotonin transporter (Sanchez and Hyttel 1999) and 
this potency may be a signiﬁ  cant factor in the frequency of discontinuation syndromes 
for paroxetine in comparison with ﬂ  uvoxamine (Westenberg and Sandner 2006) and 
milnacipran (Moret et al 1985). Furthermore, paroxetine is unique among the SSRI 
because its relatively high afﬁ  nity for muscarinic receptors is similar to that of imip-
ramine (Schatzberg et al 1997; Sanchez and Hyttel 1999). A cholinergic rebound, 
as observed on withdrawal of tricyclic antidepressants (Dilsaver et al 1987), could 
also partly explain the discontinuation syndrome paroxetine. Neither ﬂ  uvoxamine 
nor milnacipran have any signiﬁ  cant afﬁ  nity for the muscarinic receptor (Moret et al 
1985; Sanchez and Hyttel 1999).Neuropsychiatric Disease and Treatment 2007:3(1) 182
Okada 
Pharmacokinetics are thought to play an important role 
in the incidence of withdrawal effect, with compounds with 
shorter half-lives having the greatest incidence of withdrawal 
effects. The apparent correlation between the occurrence of 
SSRI discontinuation syndrome and shorter drug half-lives 
has been highlighted (Schatzberg et al 1997). The half-life of 
paroxetine (21 h) may explain the relatively high incidence 
of discontinuation syndromes compared with ﬂ  uoxetine 
which has a long half-life (parent compound 1–6 days, active 
metabolite 7–9 days). Pharmacokinetic factors, however, 
do not explain the low incidence of withdrawal effects with 
milnacipran, since the half-life of the SNRI (8 h) is shorter 
than that of paroxetine (Puozzo et al 1998).  
It is possible that low incidence of withdrawal effects 
with milnacipran may be related to its dual action on the 
reuptake of noradrenaline and serotonin compared with the 
selective effect of SSRI such as paroxetine on the reuptake 
of serotonin. It seems unlikely, however, that a simple 
action on the noradrenaline transporter is sufﬁ  cient to explain 
the situation. Firstly, paroxetine is the SSRI with the high-
est afﬁ  nity for the noradrenaline transporter (Sanchez and 
Hyttel 1999) and, secondly, the SNRI venlafaxine has an 
incidence almost as high as paroxetine (Trenque et al 2002). 
Although venlafaxine is considered to be a SNRI, it is, in 
fact, a preferential serotonin reuptake inhibitor and produces 
clinically relevant inhibition of noradrenaline reuptake only 
at high doses where serotonin reuptake is very extensively 
inhibited (Harvey et al 2000).
A unique property of milnacipran which may be relevant 
is the fact that it inhibits both noradrenaline and serotonin 
reuptake with similar potency (Moret and Briley 1997). A 
recent study of changes in long-term potentiation following 
repeated treatment with milnacipran (Tachibana et al 2006) 
has shown that interactions between noradrenergic and sero-
tonergic mechanisms play an important role in the modula-
tion of synaptic plasticity. It is thus possible that the balance 
between serotonergic and noradrenergic neurotransmission 
may be essential in determining the nature and extent of 
withdrawal-related symptoms. Further preclinical and clinical 
studies are required to test this hypothesis. 
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Table1 Number and ratios of discontinuation syndrome with 
SSRIs and SNRI in our clinic
Drug  Total  number   Discontinuation  % of patients 
 of  patients  syndrome
Paroxetine 453  55  12.1
Fluvoxamine 1306  63  4.8
Milnacipran 916  6  0.7
Note: Signiﬁ  cances between subgroups:
• Paroxetine vs ﬂ  uvoxamine, p < 0.001 (χ2 = 28.78, df = 1).
• Paroxetine vs milnacipran, p < 0.001 (χ2 = 93.93, df = 1).